Linkedin
RLS logo_header
Linkedin

Typewriter Therapeutics Emerges from Stealth with $56 Million Series A Financing to pursue in vivo CAR T medicines

“By inserting a durable, functioning gene into a safe-harbor site in T cells using lipid nanoparticle-delivered RNA, our technology is designed to create safer, re-dosable genetic medicines that are accessible to many more patients than current cumbersome and complex CAR T approaches,” said Matthew Stanton, PhD, Chief Executive Officer and Board Director of Typewriter Therapeutics. “This financing enables us to build on the proof-of-concept we have established in humanized mouse models and establish our first in vivo CAR T development candidate.”

Read the full story on "Typewriter Therapeutics Emerges from Stealth with $56 Million Series A Financing to pursue in vivo CAR T medicines"

Share:

More News

AstraZeneca completes global license agreement for oral EGFR inhibitor Zegfrovy for lung cancer

AstraZeneca announced the successful completion of the previously announced exclusive license agreement with Dizal Pharmaceutical Co., Ltd for Zegfrovy (sunvozertinib), an oral irreversible epidermal growth factor receptor (EGFR) inhibitor for patients with lung cancer. Through this agreement, AstraZeneca has acquired worldwide rights to develop and commercialise Zegfrovy.

Styx Biotechnologies Announces Strategic Agreement with ZoeNCure Therapeutics to Accelerate Next-Gen ADC Pipeline to Clinic

“This agreement represents an important step in our strategy to advance our most promising ADC programs efficiently while preserving long-term value,” said Ashutosh Tiwari, PhD, Chief Executive Officer of Styx Biotechnologies. “This collaboration creates a capital-efficient path to first-in-human development by allowing Styx to clinically de-risk selected programs while preserving

INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Ph 2 HNSCC Study

“What is most exciting to us is the depth and durability of the responses we are seeing with INBRX-106, particularly in HPV+ disease,” said Mark Lappe, co-founder and Chief Executive Officer of Inhibrx. “These results strengthen our conviction in OX40-mediated T-cell costimulation and give us a strong rationale to expand

Treeline Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate TLN-121 with CD20xCD3 T-Cell-Engaging Bispecific Antibodies

“CD20xCD3 T-cell-engaging bispecific antibodies such as glofitamab and mosunetuzumab have already transformed the treatment of B-cell lymphomas. We are excited to build on that progress in collaboration with Roche,” said Josh Bilenker, M.D., co-founder and Chief Executive Officer of Treeline. “We have generated exciting preclinical data suggesting that TLN-121 enhances